Johnson & Johnson (NYSE: JNJ) Vision today announced a strategic contact lens partnership with Menicon.
J&J Vision and Menicon have teamed up to offer a new portfolio of products and services for treating the progression of myopia, sometimes known as “myopia,” in children, according to a press release.
Menicon will manufacture therapeutic contact lenses designed to treat the progression of myopia in children, and J&J Vision will be responsible for expanding the availability of lenses worldwide.
“Over the decades, Johnson & Johnson Vision has invested in scientific partnerships with academic centers, research institutions and leading global health organizations that share our vision of leadership in science to transform the future of myopia and eye health,” said Peter Menziuso, Global President of J&J Vision Care … the release says. “Our partnership with Menicon marks another step forward towards creating a portfolio of differentiated products that will help manage the progression of myopia in children as we work on our vision of helping the world see better, communicate better and live better.”